The Ebola epidemic



Ethics Guidance

Vânia de la Fuente-Núñez, MD, MA (On behalf of the GHE Unit) Dublin, 25 May 2015



Objective

- Overview of the ethical issues identified during the Ebola epidemic and the recommendations provided in response
- Work of WHO in Ethics during Ebola epidemic:
 - Meeting Reports
 - Guidance documents



Background

1. First Meeting of the IHR Emergency Committee: 6-7 August

 Public Health Emergency of International Concern: high public health risk posed by the epidemic to all States

2. On 11 August, WHO convened an Ethics Panel



Ethics Panel - 11 August

Purpose

What are the ethical implications of using unregistered interventions that have not yet been evaluated for safety and efficacy in humans?

Outcome

"In the **exceptional situation of the current Ebola outbreak**, there is an ethical imperative to offer the available unregistered interventions that have shown promising results in the laboratory and in relevant animal models to patients and people at high risk of developing the disease..."

Moral obligation to collect and share data **rapidly** and **transparently**

Use of Els should <u>**not**</u> interfere with containment and supportive care strategies





Ethics Panel - 11 August

- Departure from the historically evolved system of regulation and governance of therapies and interventions
- Raised further questions/challenges, which requested further guidance

5



Questions to be answered

- In what context should experimental interventions (EIs) be used?
- 2. Methodologically, **which type of study designs** could provide interpretable data in situations where placebo controlled trials were either unfeasible or unacceptable to the local population?
- 3. Should **children and pregnant women** be excluded from these early studies?



6



1. In what context should Els be used?

 Urgent need to gather sound evidence on safety and efficacy, and limited window of opportunity for research → Research setting.

Research

• Need to fast track the drug development pathway

Should not equate to cutting corners

WHO Working Group Meetings:11 August; 4-5 Sept 2014; 20-21 Oct 2014 Guidance document: MEURI

1. In what context should Els be used?

 Urgent need to gather sound evidence on efficacy and safety, and limited window of opportunity for research → Research setting.

- When outside of research, avoid term "compassionate use"
 - Term associated with a presumed benefit
 - Does not reflect the urgent need to collect data

Compassionate Use?

Research

Monitored Emergency Use of Unregistered Interventions: MEURI

MEURI

WHO Working Group Meetings:11 August; 4-5 Sept 2014; 20-21 Oct 2014 Guidance document: MEURI

8

2. Which type of study designs?

- All decisions related to use of EI should be aligned with the aim to learn as much as possible, as <u>quickly</u> as possible, without compromising <u>patient care</u> and health worker <u>safety</u>.
- The use of placebo and randomization may not be feasible or acceptable in the affected countries
- An adaptive design may be preferable given that:
 - It has the capacity to yield meaningful and interpretable data quickly and early in the trial
 - Study can be **modified** based on early findings
 - Potential to have high impact on mortality

WHO Working Group Meetings: 4-5 Sept 2014; 20-21 Oct 2014



3. Inclusion of vulnerable populations?

- May need to reconsider existing guidance on the **exclusion** of:
 - Children in trials with potentially effective therapies for Ebola in light of:
 - High risk of mortality from EVD
 - Need to gather data on safety and efficacy in this population
 - Pregnant women in trials with potentially effective therapies for Ebola in light of:
 - Same arguments as with children
 - Existing evidence: fetuses and born babies do not survive

<u>Guidance documents</u>: Involvement of Children in Research or MEURI; Inclusion of pregnant women in clinical research or MEURI



Other issues

- Healthcare workers' obligations
- Data sharing and access; Biobanking
- Developing the notion of MEURI
- Isolation and Quarantine measures
- Priority setting for access to vaccines, treatments and other resources
- Vaccine trials during an epidemic
- Ethics of using Convalescent Whole Blood and plasma

Guidance in progress/to be developed

<u>Guidance documents</u>: HCW obligations during the Ebola epidemic; MEURI; Vaccine Trials <u>WHO Working Group Meeting</u>: 4-5 Sept 2014



Use of convalescent whole blood/plasma

- One of the **prioritized** experimental interventions by the Scientific Technical Advisory Committee
- **Specific recommendations** on the use of these interventions:
 - Analysis of ethical issues related to donors, recipients and healthcare workers
- Use of CWB/CP in the field raised further issues in relation to ownership and management of the excess of blood/plasma samples

 $\underline{\textit{Guidance document}}: Ethics of using CWB/CP during the Ebola epidemic$





Next steps

- Next steps:
 - From Ebola Virus Disease to Epidemics
 - From Research to Public Health Actions



Discussion

• The wrong questions asked?

- Inappropriate focus on experimental treatments for individuals?
- New guidance on HCW obligations?





Thank you!

Acknowledgements:

Abha Saxena, Andreas Reis, Marisol Guraiib Global Health Ethics, WHO-HQ

Contact: delafuentenunezv@who.int












The resulting actions from August 11th

Research Protocols

In less than 5 months, 47 **registered trials** in ICTRP, of which 17 are on treatment, 28 on prevention and 2 on diagnostics.



Compassionate Use?

Some interventions that were **not** approved, either scientifically or ethically, were given to patients on the basis of compassionate use.



Drugs and Vaccines in approved trials

18



Discussion on Study Designs

Study design	Advantages	Disadvantages
RCT "The Gold Standard"	 Achieve answer quickly with relatively small sample size Remove selection bias and control for variation 	 Unethical? Unfeasible? Unsafe? No consensus on comparator Risk of poor compliance
Stepped Wedge Design	 Randomization by cluster may be more acceptable Potential higher compliance Staggering may make it easier to implement Realistic mirror of availability of drugs 	 Logistical difficulties Complex statistical analysis Need to control for temporal trends to mitigate bias Risk of "gravitation"
RCT with stepped roll- out	 Can be rolled out more rapidly than RCT Adaptability Randomization Maximum follow-up time 	 Requires a control group Logistical challenges Complex randomization process
Cluster Randomized Trial	Greater acceptability?Less complexIncludes control group	Larger sample sizes?Complex statistical analysisRisk of "gravitation"
Single Arm non- comparative study	 Early availability of control data Relatively small sample size More acceptable? Easier implementation 	 Higher potential risk for bias Lack of consent from historical control group



ii. Research with Els and Study Design

<u>Ethical considerations</u> in selecting a particular design and a particular intervention:

Drug	Design	Site	Participant	Institutional
 Prior knowledge Number of doses available now/future Ease of admin and monitoring Risk to healthcare workers Additional support? 	 Number of participants required Time required Bias (internal consistency) Complexity 	 Human resources Infrastructure 	 Equity Access Distribution of benefits and risks Acceptability Complexity of community engagement 	 Capacity for ethics review



iv. Els and vaccine trials

- Different ethical considerations between prophylaxis and therapeutics :
 - Healthy, uninfected individuals vs. Infected Individuals
 - Low vs. High risks to healthcare workers
- Different ethical considerations between pre-exposure prophylaxis and post-exposure prophylaxis
 - Presumably uninfected individuals vs. infected individuals
 - Low vs. High risks to healthcare workers
- Reconsideration of study designs

Guidance document: Ethics of Vaccine Trials and different study designs



Ethics Consultation: Advisors

Name	Affiliation	Country
Prof M. Selgelid	Director Centre for Human Bioethics, Monash University	Australia
Dr. P. Calain (Chair)	Unité de Recherche, MSF	Switzerland
Prof. A. Toure	Head of Immunology Department, Pasteur Institute	Senegal
Prof. R. Upshur	Canada Research Chair in Primary Care Research; Professor, University of Toronto	Canada
Prof. P. Smith	Professor of Tropical Epidemiology, LSHTM	UK
Dr. H.B. Ndagije	Head of the Drug Information Department in the Ugandan National Drug Authority	Uganda
Prof J. Farrar	Director, Wellcome Trust	UK
Prof R. Ida	Member of the Expert Panel on Bioethics	Japan
Ms. J.Thomas	Patient Safety Champion	USA
Dr. J.P. Beca	Professor, Bioethics Center at Universidad del Desarrollo	Chile
Prof. T. Madani	Professor of internal medicine and infectious diseases	Saudi Arabia
Dr. M. Danis	Head, Sect. on Ethics & Health Policy (NIH)	USA



Ethics Consultation: Resource Persons

Name	Affiliation	Country
Dr. S. Monroe	CDC, US-FDA	USA
Prof. L.Borio	US-FDA	USA
Dr. F.Hayden	U Virginia	USA
Dr. D. Baush	U.S. Naval Medical Research Unit No.6 Lima	Peru



Questions to be answered

- 1. Under what conditions could potential therapeutic agents be given outside of a research context?
- 2. How could the drug development pathways be ethically fasttracked?
- 3. Would placebo-controlled trials be acceptable under the prevailing circumstances?
- 4. Given the scarce data on efficacy and safety of the proposed interventions, and the moral duty to protect vulnerable populations from harm and exploitation, should children and pregnant women be excluded from these early studies?
- 5. Would the same ethical considerations apply to potential therapeutics and vaccines?



Questions to be answered


- Most of the questions can be broadly grouped under Research Ethics
 - 1. Trial design
 - 2. Inclusion of vulnerable populations in research
 - 3. Prioritization of research
- The discussion is compounded by at least two factors:
 - -Early stage experimental interventions
 - -Outbreak context





Figure 3.1

International public health security: a global network of national health systems and technical partners, focused on four major areas of work, coordinated by WHO



Core functions of the IHR




The IHR help countries to prevent, detect, inform about and respond to public health events in a facilitated manner.



Conclusion

- Next steps:
 - From Research to Public Health Action
 - From EVD to Epidemics
- Guidance development chronology:







- From EVD to Epidemics
- From Research to Public Health Actions



i. In what context should Els be used?

 Urgent need to gather sound evidence on efficacy and safety, and limited window of opportunity for research → Research setting.

Research

• Need to fast track the drug development pathway

- Should not equate to cutting corners
- Guidance needed for fast-tracking ethics review

WHO Working Group Meetings:11 August; 4-5 Sept 2014; 20-21 Oct 2014 Guidance document: MEURI



i. In what context should Els be used?

- When outside of research, avoid term "compassionate use"
 - Term associated with a presumed benefit and a concurrent clinical trial
 - Does not reflect the urgent need to collect data

Compassionate Use?

- Monitored Emergency Use of Unregistered Interventions: MEURI
 - Denotes emergency
 - Reflects urgent need to gather data
 - No presumed benefit associated with the term



WHO Working Group Meetings:11 August; 4-5 Sept 2014; 20-21 Oct 2014 Guidance document: MEURI

